CD95 predicts responsiveness to tretinoin in acute promyelocytic leukemia.

International journal of molecular medicine

Volumn 1, Issue 1, 1998, Pages 207-211

  Tomizuka, H ^a   Hatake, K ^a   Ikeda, M ^a   Gunji, Y ^a   Ikeda, K ^a   Takizawa, T ^a   Saito, T ^a   Hoshino, Y ^a   Ohtsuki, T ^a   Takahashi, H ^a   Yonehara, S ^a   Miura, Y ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CD11B ANTIGEN; CD33 ANTIGEN; CD34 ANTIGEN; DIFFERENTIATION ANTIGEN; FAS ANTIGEN; LEUKOCYTE ANTIGEN; ONCOPROTEIN; PROMYELOCYTIC LEUKEMIA RETINOIC ACID RECEPTOR ALPHA FUSION ONCOPROTEIN; PROMYELOCYTIC LEUKEMIA-RETINOIC ACID RECEPTOR ALPHA FUSION ONCOPROTEIN; RETINOIC ACID; TUMOR PROTEIN;

ADULT; ARTICLE; FEMALE; GENETICS; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; PROMYELOCYTIC LEUKEMIA;

ADULT; ANTIGENS, CD; ANTIGENS, CD34; ANTIGENS, CD95; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; FEMALE; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MACROPHAGE-1 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM PROTEINS; ONCOGENE PROTEINS, FUSION; TRETINOIN;

EID: 0031598823     PISSN: 11073756     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijmm.1.1.207     Document Type: Article

References (0)